These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 8398333

  • 1. Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).
    Chauvergne J, Fumoleau P, Cappelaere P, Metz R, Armand JP, Chevallier B, Kerbrat P, de Forni M, Lhommé C, Roche H.
    Eur J Cancer; 1993; 29A(3):350-4. PubMed ID: 8398333
    [Abstract] [Full Text] [Related]

  • 2. [Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients].
    Nagao S, Okimoto N, Hongo A, Mizutani Y, Kodama J, Yoshinouchi M, Hiramatsu Y, Kudo T.
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):243-9. PubMed ID: 12610873
    [Abstract] [Full Text] [Related]

  • 3. [Preliminary phase II clinical study of 4'-O-tetrahydropyranyl doxorubicin (THP-ADM)].
    Majima H.
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):805-10. PubMed ID: 6882000
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
    van Wijk FH, Lhommé C, Bolis G, Scotto di Palumbo V, Tumolo S, Nooij M, de Oliveira CF, Vermorken JB, European Organization for Research and Treatment of Cancer. Gynaecological Cancer Group.
    Eur J Cancer; 2003 Jan; 39(1):78-85. PubMed ID: 12504662
    [Abstract] [Full Text] [Related]

  • 5. A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
    Stöger H, Bauernhofer T, Schmid M, Ploner F, Moser R, Derstvenscheg E, Steindorfer P, Wilders-Truschnig M, Kuss I, Samonigg H.
    Cancer Chemother Pharmacol; 1994 Jan; 35(2):174-8. PubMed ID: 7987997
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer.
    Chevallier B, Mignot L, Delozier T, Morvan F, Ferme C, Herait P.
    Am J Clin Oncol; 1992 Oct; 15(5):395-8. PubMed ID: 1524040
    [Abstract] [Full Text] [Related]

  • 7. [Phase II study of 4'-O-tetrahydropyranyl-adriamycin (THP-ADM) in patients with gynecological cancer].
    Kato T, Nishimura H, Umezu J, Takeuchi S, Kanazawa K, Inoue H, Suzuki M, Hirono M, Suzuki T, Okajima H.
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):1962-7. PubMed ID: 4051511
    [Abstract] [Full Text] [Related]

  • 8. 4'-O-tetrahydropyranyl-doxorubicin in advanced breast cancer: a phase II study.
    Samonigg H, Kasparek AK, Stöger H, Schmid M, Eber B, Stark G, Weinrauch V, Pfeiffer K, Smola M, Steindorfer P.
    Cancer Chemother Pharmacol; 1990 Oct; 26(4):293-6. PubMed ID: 2369794
    [Abstract] [Full Text] [Related]

  • 9. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [Abstract] [Full Text] [Related]

  • 10. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN.
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [Abstract] [Full Text] [Related]

  • 11. Epirubicin: clinical toxicity during the phase II program in endometrial and cervical cancer.
    Calero F, Jimeno J, Rodríguez-Escudero F, Asins Codoner J, Mendana J, Iglesias J, Murillo F, Ugalde F, Armas A, Rementería A.
    Eur J Gynaecol Oncol; 1992 Jul; 13(1):83-9. PubMed ID: 1547798
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of pirarubicin (THP-adriamycin) in metastatic breast cancer patients.
    Lenk H, Tanneberger S, Wiener N, Giesske H, Gärtner S, Geyer J, Rotte KH.
    Oncology; 1990 Jul; 47(2):97-100. PubMed ID: 2314831
    [Abstract] [Full Text] [Related]

  • 13. Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin.
    Ogawa M, Miyamoto H, Inigaki J, Horikoshi N, Ezaki K, Inoue K, Ikeda K, Usui N, Nakada H.
    Invest New Drugs; 1983 Jul; 1(2):169-72. PubMed ID: 6678865
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
    Lévi F, Benavides M, Chevelle C, Le Saunier F, Bailleul F, Misset JL, Regensberg C, Vannetzel JM, Reinberg A, Mathé G.
    J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
    [Abstract] [Full Text] [Related]

  • 15. [A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers].
    Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamaya T.
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1681-9. PubMed ID: 1872624
    [Abstract] [Full Text] [Related]

  • 16. Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.
    Miller AA, Schmidt CG.
    Cancer Res; 1987 Mar 01; 47(5):1461-5. PubMed ID: 3815348
    [Abstract] [Full Text] [Related]

  • 17. Pirarubicin (4'-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A Clinical Phase II study.
    Scheithauer W, Samonigg H, Depisch D, Schüller J, Hausmaninger H, Wiegele J, Zielinsky C, Stöger H, Haider K, Preis P.
    Invest New Drugs; 1990 May 01; 8(2):207-10. PubMed ID: 2384308
    [Abstract] [Full Text] [Related]

  • 18. [Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group].
    Noda K, Tanaka K, Ozaki M, Hirabayasi K, Hasegawa K, Nishiya I, Yakushiji M, Izumi R, Tomoda Y, Ogita Y, Sugimori H, Yamabe T, Kudo R, Yajima A, Terashima Y, Fujii S, Suzuoki Y, Okada H, Kono I, Ochiai K, Yamamoto T, Ikeda M, Umesaki N, Saito T, Niitani H.
    Gan To Kagaku Ryoho; 1998 Nov 01; 25(13):2061-8. PubMed ID: 9838908
    [Abstract] [Full Text] [Related]

  • 19. [Intra-arterial infusion chemotherapy of advanced breast cancer--effects and side effects of adriamycin, 4'-epi-adriamycin and THP-adriamycin].
    Toda K, Asaishi K, Okazaki M, Okazaki Y, Okazaki A, Sato H, Mikami T, Watanabe Y, Hayasaka H, Narimatsu E.
    Gan To Kagaku Ryoho; 1989 Aug 01; 16(8 Pt 2):3011-4. PubMed ID: 2782905
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer.
    Kikuyama S, Inada T, Miyakita M, Ogata Y.
    Jpn J Clin Oncol; 1998 May 01; 28(5):314-7. PubMed ID: 9703858
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.